Virus-Derived Peptides for Clinical Applications

Yang, Mingying; Sunderland, Kegan S.; Mao, Chuanbin

doi:10.1021/acs.chemrev.7b00100

Cited by 61 publications

(53 citation statements)

References 200 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are some gold‐standard materials employed for gene delivery with multiple reviews have focused on viral and nonviral gene delivery platforms . Zwitterionic lipids, for example, have been demonstrated to form a stable DNA capsule and can be administered with other formulations to enhance gene delivery in vivo .…”

Section: Challenges and Limitations For In Vivo Delivery Of Npsmentioning

confidence: 99%

Biohybrid Nanoparticles to Negotiate with Biological Barriers

Mohammadi

Corbo

Molinaro

et al. 2019

Small

View full text Add to dashboard Cite

Incapability of effective cross-talk with biological environments has partly impaired the in vivo functionality of nanoparticles (NPs). Homing, biodistribution, and function of NPs could be engineered through regulating their interactions with in vivo niches. Inspired by communications in biological systems, endowing a "biological identity" to synthetic NPs is one approach to control their biodistribution, and immunonegotiation profiles. This syntheticbiological combination is referred to as biohybrid NPs, which comprise both i) engineerable, readily producible, and trackable synthetic NPs as well as ii) biological moieties with the capability to cross-talk with immunological barriers. Here, the latest understanding on the in vivo interactions of NPs, biological barriers they face, and emerging methods for quantitative measurements of NPs' biodistribution are reviewed. Some key biomolecules that have emerged as negotiators with the immune system in the context of cancer and autoimmunity, and their inspirations on biohybrid NPs are introduced. Critical design considerations for efficient cross-talk between NPs and innate and adaptive immunity followed by hybridization methods are also discussed. Finally, clinical translation challenges and future perspectives regarding biohybrid NPs are discussed.

show abstract

Section: Challenges and Limitations For In Vivo Delivery Of Npsmentioning

confidence: 99%

Biohybrid Nanoparticles to Negotiate with Biological Barriers

Mohammadi

Corbo

Molinaro

et al. 2019

Small

View full text Add to dashboard Cite

show abstract

“…[26] These attempts suffer from the general lack of control in the three-dimensional placement of bioactive motifs.D NA nanostructures have the potential to make for more efficient and effective targeting agents because the number and location of attached motifs can be precisely controlled. Figure 2outlines the implementation for one such brain-targeting nanocarrier.ADNAn anostructure containing polyvalent, spatially patterned bioactive cues (such as virus-derived peptides) [27] could be designed to contain encapsulated therapeutic or sensing molecules.C oated with inert polymers [19] or lipids, [18] these structures would remain protected in the bloodstream after injection until they reach the brain vasculature and penetrate into the brain tissue via receptor-mediated transcytosis through the vascular endothelial cell layer. [29] Because of the addressability of DNA origami nanostructures,m ultiple targeting groups can be patterned on the particles surface allowing additional cellular targeting signals to also be attached.…”

Section: How Advancements In Dna Synthesis Will Effect Nanotechnologymentioning

confidence: 99%

From Designing the Molecules of Life to Designing Life: Future Applications Derived from Advances in DNA Technologies

et al. 2018

View full text Add to dashboard Cite

Since the elucidation of its structure, DNA has been at the forefront of biological research. In the past half century, an explosion of DNA-based technology development has occurred with the most rapid advances being made for DNA sequencing. In parallel, dramatic improvements have also been made in the synthesis and editing of DNA from the oligonucleotide to the genome scale. In this Review, we will summarize four different subfields relating to DNA technologies following this trajectory of smaller to larger scale. We begin by talking about building materials out of DNA which in turn can act as delivery vehicles in vivo. We then discuss how altering microbial genomes can lead to novel methods of production for industrial biologics. Next, we talk about the future of writing whole genomes as a method of studying evolution. Lastly, we highlight the ways in which barcoding biological systems will allow for their three-dimensional analysis in a highly multiplexed fashion.

show abstract

“…Peptide sequences are coded from a selection of twenty natural building blocks, i.e. amino acids, folding into a defined geometric 3D structure to bind or modify selected target molecules [67][68][69] . Short peptides can be efficiently digitized, thanks to their relatively facile printability 70 ; larger ones, however, often require additional modification (e.g., S-S bonds) 71 , and are hence harder to produce and fold properly.…”

Section: Box I Digitizable Therapeuticsmentioning

confidence: 99%

Digital therapeutics for distributed response to global pandemics

Hacohen¹,

Cohen

Efroni

et al. 2018

Preprint

View full text Add to dashboard Cite

Despite advances in the development of drugs and vaccines, the spread of infectious diseases remains an imminent threat to our global health, in extreme cases potentially having detrimental consequences. At present our response to this threat is based on physically distributing therapeutic material, which utilizes the same transportation networks that support the spread of the infectious agent itself. Such competition is at risk of failure in the face of a rapidly spreading pathogen, especially given the inevitable delay from the initial outbreak to the development and execution of our response. Moreover, based on our existing transportation networks, we show that such physical distribution is intrinsically inefficient, leading to an uneven concentration of the therapeutic within a small fraction of destinations, while leaving the majority of the population deprived. This suggests that outrunning a virulent epidemic can only be achieved if we develop a mitigation strategy that bypasses the existing distribution networks of biological and chemical material. Here we propose such a response, utilizing digitizable therapeutics, which can be distributed as digital sequence files and synthesized on location, exposing an extremely efficient mitigation scheme that systematically outperforms physical distribution. Our proposed strategy, based for example on nucleic acid therapeutics, is plausibly the only viable mitigation plan, based on current technology, that can face a violently spreading pathogen. Complementing the current paradigm, which ranks drugs based on efficacy, our analysis demonstrates the importance of balancing efficacy with distributability, finding that in some cases the latter plays the dominant role in the overall mitigation efficiency.When studied from the angle of its worst-case scenario, surviving a highly infectious pandemic depends on a competition between the infectious pathogen and the therapeutic technology, each racing to reach the majority of the population first. This competition confronts us with several challenges: (i) the inevitable response time R required for us to instigate a mitigation plan places the pathogen at a potentially significant spreading advantage; (ii) while the pathogen reproduces as it spreads 1-3 , a therapy must be manufactured and shipped from one or few sources, whose production and distribution capacity may be limited 4-12 ; (iii) the dissemination of antibiotics or vaccines can be hindered by various external factors, such as geopolitical and socio-economical constraints [13][14][15][16] , which have little effect on the propagation of bacteria and viruses. But even if such factors are eliminated, e.g., assuming that an effective cure already exists, stockpiled in sufficient quantities and benefits from worldwide cooperation in its distribution, it would still have to outrun the pathogen, competing along the same routes of dissemination as the epidemic, i.e. the international transportation networks 17-23 . For a rapidly progressing epidemic, such competition may f...

show abstract

Virus-Derived Peptides for Clinical Applications

Cited by 61 publications

References 200 publications

Biohybrid Nanoparticles to Negotiate with Biological Barriers

Biohybrid Nanoparticles to Negotiate with Biological Barriers

From Designing the Molecules of Life to Designing Life: Future Applications Derived from Advances in DNA Technologies

Digital therapeutics for distributed response to global pandemics

Contact Info

Product

Resources

About